These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9286047)

  • 21. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
    Podda A; Nencioni L; De Magistris MT; Di Tommaso A; Bossù P; Nuti S; Pileri P; Peppoloni S; Bugnoli M; Ruggiero P
    J Exp Med; 1990 Sep; 172(3):861-8. PubMed ID: 2201750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
    Wood N; Marshall H; White OJ; Holt PG; McIntyre P
    Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
    Sato Y; Sato H
    Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The vaccine containing recombinant pertussis toxin induces early and long-lasting protection.
    Rappuoli R
    Biologicals; 1999 Jun; 27(2):99-102. PubMed ID: 10600193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
    Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
    Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acellular pertussis vaccine in adults: adverse reactions and immune response.
    Granström M; Thorén M; Blennow M; Tiru M; Sato Y
    Eur J Clin Microbiol; 1987 Feb; 6(1):18-21. PubMed ID: 2883004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.
    Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF
    Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
    Watanabe M; Funaishi K; Takeo T; Endoh M
    Vaccine; 2000 Dec; 19(9-10):1204-10. PubMed ID: 11137258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
    Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
    Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
    Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
    Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
    Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
    J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.